Biofrontera Inc Financials
This page shows Biofrontera Inc (BFRI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Biofrontera Inc has an operating margin of -46.1%, meaning the company retains $-46 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -66.6% the prior year.
Biofrontera Inc's revenue grew 9.5% year-over-year to $37.3M, a solid pace of expansion. This earns a growth score of 56/100.
Biofrontera Inc has elevated debt relative to equity (D/E of 3.99), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Biofrontera Inc's current ratio of 1.72 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.
While Biofrontera Inc generated -$10.3M in operating cash flow, capex of $10K consumed most of it, leaving -$10.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Biofrontera Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Biofrontera Inc generates $0.58 in operating cash flow (-$10.3M OCF vs -$17.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Biofrontera Inc generated $37.3M in revenue in fiscal year 2024. This represents an increase of 9.5% from the prior year.
Biofrontera Inc's EBITDA was -$16.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.8% from the prior year.
Biofrontera Inc generated -$10.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 58.7% from the prior year.
Biofrontera Inc reported -$17.8M in net income in fiscal year 2024. This represents an increase of 11.8% from the prior year.
Biofrontera Inc earned $-3.22 per diluted share (EPS) in fiscal year 2024. This represents an increase of 75.3% from the prior year.
Biofrontera Inc held $5.9M in cash against $0 in long-term debt as of fiscal year 2024.
Biofrontera Inc had 9M shares outstanding in fiscal year 2024. This represents an increase of 484.7% from the prior year.
Biofrontera Inc's operating margin was -46.1% in fiscal year 2024, reflecting core business profitability. This is up 20.4 percentage points from the prior year.
Biofrontera Inc's net profit margin was -47.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 11.5 percentage points from the prior year.
Biofrontera Inc invested $2.1M in research and development in fiscal year 2024. This represents an increase of 2613.0% from the prior year.
Biofrontera Inc invested $10K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 100.0% from the prior year.
BFRI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M-22.6% | $9.0M+5.1% | $8.6M-18.9% | $10.6M+19.1% | $8.9M+52.1% | $5.8M-33.0% | $8.7M-13.9% | $10.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $854K-1.8% | $870K-27.9% | $1.2M | N/A | $33K+200.0% | $11K | N/A | N/A |
| SG&A Expenses | $10.0M-4.6% | $10.5M+21.7% | $8.7M-4.9% | $9.1M+5.6% | $8.6M-24.8% | $11.5M+16.9% | $9.8M-2.8% | $10.1M |
| Operating Income | -$6.3M-23.6% | -$5.1M-11.7% | -$4.5M-17.6% | -$3.9M+16.3% | -$4.6M+46.9% | -$8.7M-58.4% | -$5.5M+2.3% | -$5.6M |
| Interest Expense | N/A | $620K+416.7% | $120K+172.7% | $44K-69.0% | $142K+343.8% | $32K+1500.0% | $2K+101.7% | -$119K |
| Income Tax | $6K-71.4% | $21K+2200.0% | -$1K+83.3% | -$6K-700.0% | $1K-92.9% | $14K+180.0% | $5K | N/A |
| Net Income | -$6.6M-24.9% | -$5.3M-26.7% | -$4.2M-219.2% | $3.5M+155.6% | -$6.3M+35.5% | -$9.8M-31.5% | -$7.5M-168.5% | -$2.8M |
| EPS (Diluted) | $-0.62-8.8% | $-0.57-21.3% | $-0.47 | $4.45+195.9% | $-4.64+35.8% | $-7.23 | $-5.60 | $2.23 |
BFRI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.4M-23.5% | $20.1M+21.4% | $16.6M-40.6% | $27.9M-18.1% | $34.1M-7.6% | $36.9M-12.1% | $42.0M-17.5% | $50.9M |
| Current Assets | $14.4M-23.4% | $18.8M+22.7% | $15.3M-33.6% | $23.1M-22.1% | $29.6M-8.3% | $32.3M-13.2% | $37.2M-13.7% | $43.1M |
| Cash & Equivalents | $3.4M-52.8% | $7.2M+305.5% | $1.8M+32.9% | $1.3M-60.8% | $3.4M-23.2% | $4.5M+242.5% | $1.3M-92.4% | $17.2M |
| Inventory | $4.3M+7.5% | $4.0M-38.3% | $6.5M-40.2% | $10.9M-32.1% | $16.1M+8.7% | $14.8M+121.7% | $6.7M-6.9% | $7.2M |
| Accounts Receivable | $3.0M-24.3% | $4.0M-1.9% | $4.0M-21.9% | $5.2M+36.1% | $3.8M+73.0% | $2.2M-46.7% | $4.1M+9.8% | $3.7M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.0M-27.5% | $24.8M+53.9% | $16.1M-30.3% | $23.1M-30.0% | $33.1M+11.2% | $29.7M+17.9% | $25.2M-6.6% | $27.0M |
| Current Liabilities | $12.6M-36.2% | $19.7M+79.6% | $11.0M-39.4% | $18.1M-37.9% | $29.1M+14.9% | $25.4M+24.0% | $20.4M-2.1% | $20.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.6M+44.7% | -$4.7M-1033.6% | $500K-89.6% | $4.8M+361.8% | $1.0M-85.5% | $7.2M-57.2% | $16.8M-29.8% | $23.9M |
| Retained Earnings | -$133.6M-5.2% | -$126.9M-4.4% | -$121.6M-22.0% | -$99.7M+3.4% | -$103.2M-6.5% | -$96.8M-11.3% | -$87.0M-9.4% | -$79.5M |
BFRI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M-25.6% | -$3.0M+26.0% | -$4.1M+53.6% | -$8.9M-342.4% | -$2.0M+80.6% | -$10.3M-180.2% | -$3.7M+55.4% | -$8.3M |
| Capital Expenditures | -$1K-200.0% | $1K-66.7% | $3K+133.3% | -$9K | $0 | $0-100.0% | $14K+1300.0% | $1K |
| Free Cash Flow | -$3.8M-25.5% | -$3.0M+26.1% | -$4.1M+53.6% | -$8.9M-342.9% | -$2.0M+80.6% | -$10.3M-179.1% | -$3.7M+55.2% | -$8.3M |
| Investing Cash Flow | $1K+200.0% | -$1K+66.7% | -$3K-104.1% | $73K-80.9% | $382K+114.6% | $178K+1371.4% | -$14K+99.3% | -$2.1M |
| Financing Cash Flow | $0-100.0% | $5.3M-8.9% | $5.8M-13.6% | $6.7M+1036.0% | $591K | N/A | N/A | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BFRI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -89.8%-33.6pp | -56.3%-3.3pp | -52.9%-16.5pp | -36.5%+15.4pp | -51.9%+96.8pp | -148.8%-85.9pp | -62.9%-7.5pp | -55.4% |
| Net Margin | -95.2%-36.2pp | -59.0%-10.0pp | -48.9%-82.2pp | 33.3%+104.6pp | -71.3%+96.9pp | -168.2%-82.6pp | -85.6%-58.2pp | -27.5% |
| Return on Equity | N/A | N/A | N/A | 73.6% | N/A | N/A | N/A | N/A |
| Return on Assets | -43.1%-16.7pp | -26.4%-1.1pp | -25.3%-38.0pp | 12.6%+31.2pp | -18.6%+8.1pp | -26.7%-8.8pp | -17.8%-12.3pp | -5.5% |
| Current Ratio | 1.15+0.2 | 0.96-0.4 | 1.40+0.1 | 1.28+0.3 | 1.02-0.3 | 1.27-0.5 | 1.82-0.2 | 2.06 |
| Debt-to-Equity | -6.97-1.7 | -5.31-37.6 | 32.24+27.4 | 4.83-27.0 | 31.86+27.7 | 4.14+2.6 | 1.51+0.4 | 1.13 |
| FCF Margin | -54.7%-21.0pp | -33.7%+14.2pp | -48.0%+35.8pp | -83.8%-61.2pp | -22.5%+154.2pp | -176.7%-134.3pp | -42.4%+39.1pp | -81.5% |
Similar Companies
Frequently Asked Questions
What is Biofrontera Inc's annual revenue?
Biofrontera Inc (BFRI) reported $37.3M in total revenue for fiscal year 2024. This represents a 9.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biofrontera Inc's revenue growing?
Biofrontera Inc (BFRI) revenue grew by 9.5% year-over-year, from $34.1M to $37.3M in fiscal year 2024.
Is Biofrontera Inc profitable?
No, Biofrontera Inc (BFRI) reported a net income of -$17.8M in fiscal year 2024, with a net profit margin of -47.6%.
What is Biofrontera Inc's earnings per share (EPS)?
Biofrontera Inc (BFRI) reported diluted earnings per share of $-3.22 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Biofrontera Inc's EBITDA?
Biofrontera Inc (BFRI) had EBITDA of -$16.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biofrontera Inc's operating margin?
Biofrontera Inc (BFRI) had an operating margin of -46.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Biofrontera Inc's net profit margin?
Biofrontera Inc (BFRI) had a net profit margin of -47.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Biofrontera Inc's free cash flow?
Biofrontera Inc (BFRI) generated -$10.3M in free cash flow during fiscal year 2024. This represents a 58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biofrontera Inc's operating cash flow?
Biofrontera Inc (BFRI) generated -$10.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Biofrontera Inc's total assets?
Biofrontera Inc (BFRI) had $22.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Biofrontera Inc's capital expenditures?
Biofrontera Inc (BFRI) invested $10K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Biofrontera Inc spend on research and development?
Biofrontera Inc (BFRI) invested $2.1M in research and development during fiscal year 2024.
How many shares does Biofrontera Inc have outstanding?
Biofrontera Inc (BFRI) had 9M shares outstanding as of fiscal year 2024.
What is Biofrontera Inc's current ratio?
Biofrontera Inc (BFRI) had a current ratio of 1.72 as of fiscal year 2024, which is generally considered healthy.
What is Biofrontera Inc's debt-to-equity ratio?
Biofrontera Inc (BFRI) had a debt-to-equity ratio of 3.99 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biofrontera Inc's return on assets (ROA)?
Biofrontera Inc (BFRI) had a return on assets of -80.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Biofrontera Inc's cash runway?
Based on fiscal year 2024 data, Biofrontera Inc (BFRI) had $5.9M in cash against an annual operating cash burn of $10.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biofrontera Inc's Piotroski F-Score?
Biofrontera Inc (BFRI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biofrontera Inc's earnings high quality?
Biofrontera Inc (BFRI) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Biofrontera Inc?
Biofrontera Inc (BFRI) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.